Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Elihu Estey

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Recurrence

Anatomy

Bone Marrow

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
116
Kantarjian, Hagop
73
O'Brien, Susan
56
Keating, Michael
54
Giles, Francis
46
Beran, Miloslav
41
Keating, Michael
38
Pierce, Sherry
37
Cortes, Jorge
34
Albitar, Maher
32
Garcia-Manero, Guillermo
32
Koller, Charles
31
Faderl, Stefan
27
Freireich, Emil
27
Kantarjian, Hagop
23
Andreeff, Michael

Sign-in to see all Coauthors

Publications

TOP 3
Armistead Paul M; de Lima Marcos; Pierce Sherry; Qiao Wei; Wang Xuemei; Thall Peter F; Giralt Sergio; Ravandi Farhad; Kantarjian Hagop; Champlin Richard; Estey Elihu
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Estey Elihu
Do commonly used clinical trial designs reflect clinical reality?
Ma Wanlong; Kantarjian Hagop; Bekele Benjamin; Donahue Amber C; Zhang Xi; Zhang Zhong J; O'Brien Susan; Estey Elihu; Estrov Zeev; Cortes Jorge; Keating Michael; Giles Francis; Albitar Maher
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Elihu Estey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Armistead Paul M; de Lima Marcos; Pierce Sherry; Qiao Wei; Wang Xuemei; Thall Peter F; Giralt Sergio; Ravandi Farhad; Kantarjian Hagop; Champlin Richard; Estey Elihu
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(11):1431-8.
2009: Estey Elihu
Do commonly used clinical trial designs reflect clinical reality?
Haematologica 2009;94(10):1435-9.
2009: Ma Wanlong; Kantarjian Hagop; Bekele Benjamin; Donahue Amber C; Zhang Xi; Zhang Zhong J; O'Brien Susan; Estey Elihu; Estrov Zeev; Cortes Jorge; Keating Michael; Giles Francis; Albitar Maher
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3820-6.
2009: Huang Xuelin; Ning Jing; Li Yisheng; Estey Elihu; Issa Jean-Pierre; Berry Donald A
Using short-term response information to facilitate adaptive randomization for survival clinical trials.
Statistics in medicine 2009;28(12):1680-9.
2009: Sekeres Mikkael A; Elson Paul; Kalaycio Matt E; Advani Anjali S; Copelan Edward A; Faderl Stefan; Kantarjian Hagop M; Estey Elihu
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.
Blood 2009;113(1):28-36.
2009: Ma Wanlong; Kantarjian Hagop; Zhang Xi; Jilani Iman; Sheikholeslami Mohammad R; Donahue Amber C; Ravandi Farhad; Estey Elihu; O'Brien Susan; Keating Michael; Giles Francis J; Albitar Maher
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Cancer biomarkers : section A of Disease markers 2009;5(1):51-8.
2008: Gardner Alison; Mattiuzzi Gloria; Faderl Stefan; Borthakur Gautam; Garcia-Manero Guillermo; Pierce Sherry; Brandt Mark; Estey Elihu
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5684-8.
2008: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Wierda William; Faderl Stefan; Garcia-Manero Guillermo; Issa Jean-Pierre; Estey Elihu; Keating Michael; Freireich Emil J
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Cancer 2008;113(7 Suppl):1933-52.
2008: Tsimberidou Apostolia Maria; Estey Elihu; Wen Sijin; Pierce Sherry; Kantarjian Hagop; Albitar Maher; Kurzrock Razelle
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
Cancer 2008;113(7):1605-13.
2008: Yanada Masamitsu; Borthakur Gautam; Garcia-Manero Guillermo; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Kantarjian Hagop; Estey Elihu
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
Leukemia research 2008;32(10):1505-9.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; Keating Michael J; O'Brien Susan; Brandt Mark; Pierce Sherry; Freireich Emil J; Medeiros L Jeffrey; Estey Elihu
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Cancer 2008;113(6):1370-8.
2008: Tsimberidou Apostolia M; Estey Elihu
Relevance of clinical trials in acute myeloid leukaemia.
Hematological oncology 2008;26(3):182-3.
2008: Estey Elihu
New drugs in acute myeloid leukemia.
Seminars in oncology 2008;35(4):439-48.
2008: Yanada Masamitsu; Borthakur Gautam; Ravandi Farhad; Bueso-Ramos Carlos; Kantarjian Hagop; Estey Elihu
Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.
Haematologica 2008;93(8):1263-5.
2008: Quezada Gerardo; Kopp Lisa; Estey Elihu; Wells Robert J
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Pediatric blood & cancer 2008;51(1):133-5.
2008: Yanada Masamitsu; Garcia-Manero Guillermo; Borthakur Gautam; Ravandi Farhad; Kantarjian Hagop; Estey Elihu
Relapse and death during first remission in acute myeloid leukemia.
Haematologica 2008;93(4):633-4.
2008: Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda W G; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(3):538-43.
2008: Estey Elihu
Response in acute myeloid leukemia.
Clinical advances in hematology & oncology : H&O 2008;6(2):113-7.
2007: Yanada Masamitsu; Garcia-Manero Guillermo; Borthakur Gautam; Ravandi Farhad; Kantarjian Hagop; Estey Elihu
Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.
Cancer 2007;110(12):2756-60.
2007: Atallah Ehab; Cortes Jorge; O'Brien Susan; Pierce Sherry; Rios Mary Beth; Estey Elihu; Markman Maurie; Keating Michael; Freireich Emil J; Kantarjian Hagop
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood 2007;110(10):3547-51.
2007: Yanada Masamitsu; Huang Xuelin; Garcia-Manero Guillermo; O'brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Issa Jean-Pierre; Kantarjian Hagop; Estey Elihu
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
British journal of haematology 2007;138(4):555-7.
2007: Aribi Ahmed; Bueso-Ramos Carlos; Estey Eli; Estrov Zeev; O'Brien Susan; Giles Francis; Faderl Stefan; Thomas Deborah; Kebriaei Partow; Garcia-Manero Guillermo; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Leukemia research 2007;31(6):791-7.
2007: Estey Elihu
Acute myeloid leukemia and myelodysplastic syndromes in older patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(14):1908-15.
2007: Kornblau Steven M; Banker Deborah E; Stirewalt Derek; Shen Danny; Lemker Elizabeth; Verstovsek Srdan; Estrov Zeev; Faderl Stefan; Cortes Jorge; Beran Miloslav; Jackson C Ellen; Chen Wenjing; Estey Elihu; Appelbaum Frederick R
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Blood 2007;109(7):2999-3006.
2007: Boumber Yanis A; Kondo Yutaka; Chen Xuqi; Shen Lanlan; Gharibyan Vazganush; Konishi Kazuo; Estey Elihu; Kantarjian Hagop; Garcia-Manero Guillermo; Issa Jean-Pierre J
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
Cancer research 2007;67(5):1997-2005.
2007: Konoplev Sergej; Rassidakis Georgios Z; Estey Elihu; Kantarjian Hagop; Liakou Chrysoula I; Huang Xuelin; Xiao Lianchun; Andreeff Michael; Konopleva Marina; Medeiros L Jeffrey
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
Cancer 2007;109(6):1152-6.
2007: Estey Elihu; de Lima Marcos; Tibes Raoul; Pierce Sherry; Kantarjian Hagop; Champlin Richard; Giralt Sergio
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Blood 2007;109(4):1395-400.
2006: Ahmed Bilal; Estey Elihu; Manning John; David Cynthia; Keating Michael J; Kantarjian Hagop; Tsimberidou Apostolia-Maria
Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.
Haematologica 2006;91(12 Suppl):ECR55.
2006: Zeng Zhihong; Samudio Ismael J; Munsell Mark; An Jing; Huang Ziwei; Estey Elihu; Andreeff Michael; Konopleva Marina
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Molecular cancer therapeutics 2006;5(12):3113-21.
2006: Estey Elihu; Döhner Hartmut
Acute myeloid leukaemia.
Lancet 2006;368(9550):1894-907.
2006: Tsimberidou Apostolia-Maria; Kantarjian Hagop; Keating Michael J; Estey Elihu
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Leukemia & lymphoma 2006;47(11):2282-8.
2006: Garcia-Manero Guillermo; Kantarjian Hagop M; Sanchez-Gonzalez Blanca; Yang Hui; Rosner Gary; Verstovsek Srdan; Rytting Michael; Wierda William G; Ravandi Farhad; Koller Charles; Xiao Lianchun; Faderl Stefan; Estrov Zeev; Cortes Jorge; O'brien Susan; Estey Elihu; Bueso-Ramos Carlos; Fiorentino Jackie; Jabbour Elias; Issa Jean-Pierre
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Levis Mark; Brown Patrick; Smith B Douglas; Stine Adam; Pham Rosalyn; Stone Richard; Deangelo Daniel; Galinsky Ilene; Giles Frank; Estey Elihu; Kantarjian Hagop; Cohen Pamela; Wang Yanfeng; Roesel Johannes; Karp Judith E; Small Donald
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood 2006;108(10):3477-83.
2006: Tsimberidou Apostolia-Maria; Estey Elihu
Induction mortality risk in adult acute myeloid leukemia.
Leukemia & lymphoma 2006;47(7):1199-200.
2006: Tsimberidou Apostolia-Maria; Tirado-Gomez Maribel; Andreeff Michael; O'Brien Susan; Kantarjian Hagop; Keating Michael; Lopez-Berestein Gabriel; Estey Elihu
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Leukemia & lymphoma 2006;47(6):1062-8.
2006: Razzouk Bassem I; Estey Elihu; Pounds Stanley; Lensing Shelly; Pierce Sherry; Brandt Mark; Rubnitz Jeffrey E; Ribeiro Raul C; Rytting Michael; Pui Ching-Hon; Kantarjian Hagop; Jeha Sima
Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions.
Cancer 2006;106(11):2495-502.
2006: Estey Elihu; Garcia-Manero Guillermo; Ferrajoli Alessandra; Faderl Stefan; Verstovsek Srdan; Jones Dan; Kantarjian Hagop
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Blood 2006;107(9):3469-73.
2006: Albitar Maher; Potts Steven J; Giles Francis J; O'Brien Susan; Keating Michael; Thomas Deborah; Clarke Charlotte; Jilani Iman; Aguilar Christine; Estey Elihu; Kantarjian Hagop
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
Cancer 2006;106(7):1587-94.
2006: Kantarjian Hagop; Beran Miloslav; Cortes Jorge; O'Brien Susan; Giles Francis; Pierce Sherry; Shan Jianqin; Plunkett William; Keating Michael; Estey Elihu
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Kantarjian Hagop; O'brien Susan; Cortes Jorge; Giles Francis; Faderl Stefan; Jabbour Elias; Garcia-Manero Guillermo; Wierda William; Pierce Sherry; Shan Jianqin; Estey Elihu
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Beran Miloslav; Shen Yu; Onida Francesco; Wen Sijin; Kantarjian Hagop; Estey Elihu
Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Leukemia & lymphoma 2006;47(3):417-23.
2006: Patel Sandip P; Garcia-Manero Guillermo; Ferrajoli Alexandra; Faderl Stefan; Verstovek Serge; Kantarjian Hagop; Estey Elihu
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Leukemia research 2006;30(3):362-3.
2006: Jabbour Elias J; Estey Elihu; Kantarjian Hagop M
Adult acute myeloid leukemia.
Mayo Clinic proceedings. Mayo Clinic 2006;81(2):247-60.
2006: Tsimberidou Apostolia-Maria; Giles Francis J; Estey Elihu; O'Brien Susan; Keating Michael J; Kantarjian Hagop M
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2005: Levine Ross L; Loriaux Marc; Huntly Brian J P; Loh Mignon L; Beran Miroslav; Stoffregen Eric; Berger Roland; Clark Jennifer J; Willis Stephanie G; Nguyen Kim T; Flores Nikki J; Estey Elihu; Gattermann Norbert; Armstrong Scott; Look A Thomas; Griffin James D; Bernard Olivier A; Heinrich Michael C; Gilliland D Gary; Druker Brian; Deininger Michael W N
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood 2005;106(10):3377-9.
2005: Jelinek Jaroslav; Oki Yasuhiro; Gharibyan Vazganush; Bueso-Ramos Carlos; Prchal Josef T; Verstovsek Srdan; Beran Miloslav; Estey Elihu; Kantarjian Hagop M; Issa Jean-Pierre J
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Blood 2005;106(10):3370-3.
2005: Ricciardi M R; McQueen T; Chism D; Milella M; Estey E; Kaldjian E; Sebolt-Leopold J; Konopleva M; Andreeff M
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1543-9.
2005: Meyers Christina A; Albitar Maher; Estey Elihu
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2005;104(4):788-93.
2005: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Faderl Stephan; Verstovsek Srdan; Thomas Deborah; Garcia-Manero Guillermo; Wierda William; Ferrajoli Alessandra; Kornblau Stephen; Mattiuzzi Gloria N; Tsimberidou Apostolia M; Albitar Maher; O'Brien Susan M; Estey Elihu
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Estey E
Therapeutic research in untreated acute promyelocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):913-5.
2005: McLaughlin Peter; Estey Elihu; Glassman Armand; Romaguera Jorge; Samaniego Felipe; Ayala Ana; Hayes Kimberly; Maddox Anne Marie; Preti H Alejandro; Hagemeister Fredrick B
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Blood 2005;105(12):4573-5.
2005: Cortes Jorge; Faderl Stefan; Estey Elihu; Kurzrock Razelle; Thomas Deborah; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Giles Francis; Koller Charles; O'Brien Susan; Wright John; Bai Stephen A; Kantarjian Hagop
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Wong Raymond; Shahjahan Munir; Wang Xuemei; Thall Peter F; De Lima Marcos; Khouri Issa; Gajewski James; Alamo Jorge; Couriel Daniel; Andersson Borje S; Donato Michelle; Hosing Chitra; Komanduri Krishna; Anderlini Paolo; Molldrem Jeffrey; Ueno Naoto T; Estey Elihu; Ippoliti Cindy; Champlin Richard; Giralt Sergio
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(2):108-14.
2005: Estey Elihu; Koller Charles; Tsimberidou Apostolia M; O'Brien Susan; Beran Miloslav; Cortes Jorge; Tirado-Gomez Maribel; Lopez-Berestein Gabriel; Kantarjian Hagop
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.
Blood 2005;105(3):1366-7.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2005: Stone Richard M; DeAngelo Daniel J; Klimek Virginia; Galinsky Ilene; Estey Eli; Nimer Stephen D; Grandin Wilson; Lebwohl David; Wang Yanfeng; Cohen Pamela; Fox Edward A; Neuberg Donna; Clark Jennifer; Gilliland D Gary; Griffin James D
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood 2005;105(1):54-60.
2005: Kindler Thomas; Breitenbuecher Frank; Kasper Stefan; Estey Eli; Giles Francis; Feldman Eric; Ehninger Gerhard; Schiller Gary; Klimek Virginia; Nimer Stephen D; Gratwohl Alois; Choudhary Chuna Ram; Mueller-Tidow Constan; Serve Hubert; Gschaidmeier Harald; Cohen Pamela S; Huber Christoph; Fischer Thomas
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood 2005;105(1):335-40.
2004: Estey E
Clinical trials in AML of the elderly: should we change our methodology?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(11):1772-4.
2004: Tsimberidou Apostolia-Maria; Estey Elihu; Whitman Gary J; Dryden Mark J; Ratnam Suresh; Pierce Sherry; Faderl Stefan; Giles Francis; Kantarjian Hagop M; Garcia-Manero Guillermo
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leukemia research 2004;28(9):991-4.
2004: Odabasi Zekaver; Mattiuzzi Gloria; Estey Elihu; Kantarjian Hagop; Saeki Fumihiro; Ridge Richard J; Ketchum Paul A; Finkelman Malcolm A; Rex John H; Ostrosky-Zeichner Luis
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(2):199-205.
2004: Beran Miloslav; Luthra Rajyalakshmi; Kantarjian Hagop; Estey Elihu
FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.
Leukemia research 2004;28(6):547-50.
2004: Cortes Jorge; Thomas Deborah; Koller Charles; Giles Francis; Estey Elihu; Faderl Stefan; Garcia-Manero Guillermo; McConkey David; Ruiz Stacey L; Guerciolini Roberto; Wright John; Kantarjian Hagop
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3371-6.
2004: Tsao Anne S; Kantarjian Hagop; Thomas Deborah; Giles Francis; Cortes Jorge; Garcia-Manero Guillermo; Huh Yang; Yang Ying; Shen Yu; Albitar Maher; Estey Elihu
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.
Leukemia research 2004;28(4):373-8.
2004: Giles Francis J; Cortes Jorge E; Kantarjian Hagop M; O'Brien Susan M; Estey Elihu; Beran Miloslav
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Leukemia research 2004;28(4):353-7.
2004: Rogers Anna; Joe Youngson; Manshouri Taghi; Dey Amanda; Jilani Iman; Giles Francis; Estey Elihu; Freireich Emil; Keating Michael; Kantarjian Hagop; Albitar Maher
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
Blood 2004;103(7):2799-801.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; Faderl Stefan; Lim JoAnn; Kontoyiannis Dimitrios; Thomas Deborah; Wierda William; Raad Isaam; Garcia-Manero Guillermo; Zhou Xian; Ferrajoli Alexandra; Bekele Nebiyou; Estey Elihu
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):581-9.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; O'Brien Susan; Kontoyiannis Dimitrios P; Giles Francis; Zhou Xian; Lim JoAnn; Bekele B Nebiyou; Faderl Stefan; Cortes Jorge; Pierce Sherry; Leitz Gerhard J; Raad Issam; Estey Elihu
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Estey Elihu
Methodologic issues in investigation of targeted therapies in acute myeloid leukemia.
Advances in pharmacology (San Diego, Calif.) 2004;51():99-106.
2004: Stone R M; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland D G; Griffin J D
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Annals of hematology 2004;83 Suppl 1():S89-90.
2004: Andreeff M; Milella M; Carter B Z; Tabe Y; Ricciardi M R; Sneed T; Ruvolo P; Contractor R; Tsao T; Schober W; Evans R; McQueen T; Zeng Z; Kornblau S M; McCubrey J; Estey E; Mills G B; Reed J C; Konopleva M
Targeted therapy of AML new concepts.
Annals of hematology 2004;83 Suppl 1():S51-3.
2004: Monaco Giuseppe; Konopleva Marina; Munsell Mark; Leysath Clinton; Wang Rui-Yu; Jackson C Ellen; Korbling Martin; Estey Elihu; Belmont John; Andreeff Michael
Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival.
Stem cells (Dayton, Ohio) 2004;22(2):188-201.
2003: Tsimberidou Apostolia M; Estey Elihu; Cortes Jorge E; Garcia-Manero Guillermo; Faderl Stefan; Verstovsek Srdan; Thomas Deborah A; Ferrajoli Alessandra; Keating Michael J; O'Brien Susan; Kantarjian Hagop M; Giles Francis J
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Thomas Deborah A; Estey Elihu; Giles Francis J; Faderl Stefan; Cortes Jorge; Keating Michael; O'Brien Susan; Albitar Maher; Kantarjian Hagop
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
British journal of haematology 2003;123(3):436-41.
2003: Giles Francis; Estey Elihu; O'Brien Susan
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Cancer 2003;98(10):2095-104.
2003: Onciu Mihaela; Estey Elihu; Giles Francis J
Circulating blasts following chemotherapy in pediatric patients: implications for complete remission definition in acute leukemia.
Hematology (Amsterdam, Netherlands) 2003;8(5):295-301.
2003: Tsimberidou Apostolia; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stephan; Albitar Maher; Kantarjian Hagop; Estey Elihu; Giles Francis J
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Apostolidou Efrosyni; Cortes Jorge; Tsimberidou Apostolia; Estey Elihu; Kantarjian Hagop; Giles Francis J
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Leukemia research 2003;27(10):887-91.
2003: Beran Miloslav; O'Brien Susan; Thomas Deborah A; Tran Hai T; Cortes-Franco Jorge E; Giles Francis; Estey Elihu; Kantarjian Hagop M
Phase I study of oral topotecan in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4084-91.
2003: Tsimberidou A-M; Kantarjian H M; Estey E; Cortes J E; Verstovsek S; Faderl S; Thomas D A; Garcia-Manero G; Ferrajoli A; Manning J T; Keating M J; Albitar M; O'Brien S; Giles F J
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1100-3.
2003: Estey Elihu; Giles Francis; Cortes Jorge; Beran Miloslav; Verstovsek Srdan; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Lazo Guillermo; Kantarjian Hagop; Estey Elihu; Thomas Deborah; O'Brien Susan; Cortes Jorge
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Cancer 2003;97(9):2218-24.
2003: Verstovsek Srdan; Manshouri Taghi; Smith Franklin O; Giles Francis J; Cortes Jorge; Estey Elihu; Kantarjian Hagop; Keating Michael; Jeha Sima; Albitar Maher
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Cancer 2003;97(9):2212-7.
2003: Estey Elihu; Sanz Miguel A
Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia.
Cancer treatment reviews 2003;29(2):143-6.
2003: Apostolidou Efrosyni; Estey Elihu; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Tsimberidou Apostolia; Kantarjian Hagop; Giles Francis J
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Leukemia research 2003;27(4):301-4.
2003: Tsimberidou Apostolia; Estey Elihu; Cortes Jorge; Thomas Deborah; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Keating Michael; Albitar Maher; O'Brien Susan; Kantarjian Hagop; Giles Francis
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Cortes Jorge; Kantarjian Hagop; Albitar Maher; Thomas Deborah; Faderl Stefan; Koller Charles; Garcia-Manero Guillermo; Giles Francis; Andreeff Michael; O'Brien Susan; Keating Michael; Estey Elihu
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Jilani I; Estey E; Manshuri T; Caligiuri M; Keating M; Giles F; Thomas D; Kantarjian H; Albitar M
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):114-9.
2003: Mattiuzzi Gloria N; Estey Elihu; Raad Issam; Giles Francis; Cortes Jorge; Shen Yu; Kontoyiannis Dimitrios; Koller Charles; Munsell Mark; Beran Miloslav; Kantarjian Hagop
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):450-6.
2003: Lu Di; Nounou Randa; Beran Miloslav; Estey Elihu; Manshouri Taghi; Kantarjian Hagop; Keating Michael J; Albitar Maher
The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):441-9.
2003: Alvarado Yesid; Tsimberidou Apostolia; Kantarjian Hagop; Cortes Jorge; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Estey Elihu; Giles Francis J
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2003;51(1):87-90.
2002: Cortes Jorge; Tsimberidou Apostolia M; Alvarez Ricardo; Thomas Deborah; Beran Miloslav; Kantarjian Hagop; Estey Elihu; Giles Francis J
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2002;50(6):497-500.
2002: Huh Y O; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(11):2249-52.
2002: Jilani Iman; Estey Elihu; Huh Yang; Joe Youngson; Manshouri Taghi; Yared Marwan; Giles Francis; Kantarjian Hagop; Cortes Jorge; Thomas Deborah; Keating Michael; Freireich Emil; Albitar Maher
Differences in CD33 intensity between various myeloid neoplasms.
American journal of clinical pathology 2002;118(4):560-6.
2002: Giles Francis; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Kantarjian Hagop; Estey Elihu
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
Haematologica 2002;87(10):1114-6.
2002: Washington LaBaron T; Jilani Iman; Estey Eli; Albitar Maher
Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.
Leukemia research 2002;26(10):899-902.
2002: Garcia-Manero Guillermo; Faderl Stefan; Giles Francis; Thomas Deborah; Cortes Jorge; O'Brien Susan; Davis Jan; Kantarjian Hagop M; Estey Elihu
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Konopleva Marina; Zhao Shourong; Hu Wei; Jiang Shuwei; Snell Virginia; Weidner Douglas; Jackson C Ellen; Zhang Xin; Champlin Richard; Estey Elihu; Reed John C; Andreeff Michael
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.
British journal of haematology 2002;118(2):521-34.
2002: Verstovsek Srdan; Estey Elihu; Manshouri Taghi; Giles Francis J; Cortes Jorge; Beran Miloslav; Rogers Anna; Keating Michael; Kantarjian Hagop; Albitar Maher
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
British journal of haematology 2002;118(1):151-6.
2002: Lin Chung Wu; Manshouri Taghi; Jilani Iman; Neuberg Donna; Patel Kunal; Kantarjian Hagop; Andreeff Michael; Estrov Zeev; Beran Miloslav; Keating Michael; Estey Elihu; Albitar Maher
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
Leukemia research 2002;26(6):551-9.
2002: Jeha Sima; Smith Franklin O; Estey Elihu; Shen Yu; Liu Diane; Manshouri Taghi; Albitar Maher
Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels.
Leukemia research 2002;26(4):399-402.
2002: Lai Raymond; Estey Elihu; Shen Yu; Despa Simona; Kantarjian Hagop; Beran Miloslav; Maushouri Taghi; Quackenbuch Robert C; Keating Micheal; Albitar Maher
Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.
Cancer 2002;94(1):14-7.
2001: Milella M; Kornblau S M; Estrov Z; Carter B Z; Lapillonne H; Harris D; Konopleva M; Zhao S; Estey E; Andreeff M
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
The Journal of clinical investigation 2001;108(6):851-9.
2001: Verstovsek S; Kantarjian H; Aguayo A; Manshouri T; Freireich E; Keating M; Estey E; Albitar M
Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome.
British journal of haematology 2001;114(2):290-5.
2001: Verstovsek S; Kantarjian H; Estey E; Aguayo A; Giles F J; Manshouri T; Koller C; Estrov Z; Freireich E; Keating M; Albitar M
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(8):1165-70.
2001: Verstovsek S; Estey E; Manshouri T; Keating M; Kantarjian H; Giles F J; Albitar M
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Leukemia & lymphoma 2001;42(3):511-6.
2001: Estey E; Koller C; Cortes J; Reed P; Freireich E; Giles F; Kantarjian H
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Leukemia & lymphoma 2001;42(3):309-16.
2001: Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cancer 2001;92(1):7-14.
2001: Giles F J; Shen Y; Kantarjian H M; Korbling M J; O'Brien S; Anderlini P; Donato M; Pierce S; Keating M J; Freireich E J; Estey E
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Fleming R V; Kantarjian H M; Husni R; Rolston K; Lim J; Raad I; Pierce S; Cortes J; Estey E
Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia.
Leukemia & lymphoma 2001;40(5-6):511-20.
2001: Nguyen Q; Estey E; Raad I; Rolston K; Kantarjian H; Jacobson K; Konoplev S; Ghosh S; Luna M; Tarrand J; Whimbey E
Cytomegalovirus pneumonia in adults with leukemia: an emerging problem.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32(4):539-45.
2001: Sarriera J E; Albitar M; Estrov Z; Gidel C; Aboul-Nasr R; Manshouri T; Kornblau S; Chang K S; Kantarjian H; Estey E
Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(1):57-61.
2001: Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Investigational new drugs 2001;19(1):13-20.
2000: Faderl S; Kantarjian H M; Estey E; Manshouri T; Chan C Y; Rahman Elsaied A; Kornblau S M; Cortes J; Thomas D A; Pierce S; Keating M J; Estrov Z; Albitar M
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Cancer 2000;89(9):1976-82.
2000: Aguayo A; Kantarjian H; Manshouri T; Gidel C; Estey E; Thomas D; Koller C; Estrov Z; O'Brien S; Keating M; Freireich E; Albitar M
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Blood 2000;96(6):2240-5.
2000: Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia & lymphoma 2000;36(5-6):479-84.
2000: Keyhani A; Huh Y O; Jendiroba D; Pagliaro L; Cortez J; Pierce S; Pearlman M; Estey E; Kantarjian H; Freireich E J
Increased CD38 expression is associated with favorable prognosis in adult acute leukemia.
Leukemia research 2000;24(2):153-9.
1999: Koller C A; Kantarjian H M; Feldman E J; O'Brien S; Rios M B; Estey E; Keating M
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Cancer 1999;86(11):2246-51.
1999: Aguayo A; Estey E; Kantarjian H; Mansouri T; Gidel C; Keating M; Giles F; Estrov Z; Barlogie B; Albitar M
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood 1999;94(11):3717-21.
1999: Beran M; Estey E; O'Brien S; Cortes J; Koller C A; Giles F J; Kornblau S; Andreeff M; Vey N; Pierce S R; Hayes K; Wong G C; Keating M; Kantarjian H
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2819-30.
1999: Kornblau S M; Thall P F; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating M J; Kantarjian H; Estey E; Andreeff M
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1758-66.
1999: Vey N; Keating M; Giles F; Cortes J; Beran M; Estey E
Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.
Blood 1999;93(9):3149-50.
1999: Albitar M; Manshouri T; Kantarjian H; Keating M; Estrov Z; Faber J; Freireich E J; Pierce S; Estey E
Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.
Leukemia research 1999;23(1):63-9.
1999: Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Investigational new drugs 1999;17(1):89-95.
1999: Cortes J; O'Brien S; Estey E; Giles F; Keating M; Kantarjian H
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Investigational new drugs 1999;17(1):81-7.
1998: Beran M; Estey E; O'Brien S M; Giles F J; Koller C A; Kornblau S; Keating M; Kantarjian H M
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia & lymphoma 1998;31(5-6):521-31.
1998: Kornblau S M; Andreeff M; Hu S X; Xu H J; Patel S; Theriault A; Koller C; Kantarjian H; Estey E; Deisseroth A B; Benedict W F
Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1955-63.
1998: Keating M J; O'Brien S; Lerner S; Koller C; Beran M; Robertson L E; Freireich E J; Estey E; Kantarjian H
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Blood 1998;92(4):1165-71.
1998: Gandhi V; Xu Y Z; Estey E
Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1719-26.
1998: DeLima M; Albitar M; O'Brien S; Pierce S; Kantarjian H; Andreeff M; Fayad L; Keating M; Estey E
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
The American journal of medicine 1998;104(3):246-51.
1998: Kornblau S M; Kantarjian H; O'Brien S; Andreeff M; Koller C A; Beran M; Keating M; Estey E
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Leukemia & lymphoma 1998;28(3-4):371-5.
1997: Estey E
Prognostic factors in clinical cancer trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2591-3.
1997: Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo M G; Rios M B; Keating M; Kantarjian H
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2377-84.
1997: Estey E; deLima M; Strom S; Pierce S; Freireich E J; Keating M J
Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center.
Cancer 1997;80(11 Suppl):2176-80.
1997: de Lima M; Strom S S; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich E; Estey E
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.
Blood 1997;90(12):4719-24.
1997: Rodriguez C O; Legha J K; Estey E; Keating M J; Gandhi V
Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2107-13.
1997: Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
Blood 1997;90(8):2969-77.
1997: Estey E; Thall P; Kantarjian H; Pierce S; Kornblau S; Keating M
Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1661-4.
1997: Gandhi V; Estey E; Du M; Keating M J; Plunkett W
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1539-45.
1997: Cortes J; Kantarjian H; O'Brien S; Beran M; Estey E; Keating M; Talpaz M
A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):929-32.
1997: Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Blood 1997;89(12):4531-6.
1997: Kurzrock R; Strom S S; Estey E; O'Brien S; Keating M J; Jiang H; Adams T; Talpaz M
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1803-10.
1997: Kornblau S M; Estey E; Madden T; Tran H T; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman R A; Andreeff M
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1796-802.
1997: Kantarjian H M; O'Brien S M; Estey E; Giralt S; Beran M; Rios M B; Keating M; de Vos D; Talpaz M
Decitabine studies in chronic and acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 1():S35-6.
1997: Estey E; Thall P F; Pierce S; Kantarjian H; Keating M
Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):483-90.
1997: Estey E; Thall P; David C
Design and analysis of trials of salvage therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 1997;40 Suppl():S9-12.
1996: Keating M J; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1996: Kornblau S M; Gandhi V; Andreeff H M; Beran M; Kantarjian H M; Koller C A; O'Brien S; Plunkett W; Estey E
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(10):1563-9.
1996: Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese J L; Andreeff M; Keating M; Estey E
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 1996;88(7):2473-9.
1996: Zhang W; Piatyszek M A; Kobayashi T; Estey E; Andreeff M; Deisseroth A B; Wright W E; Shay J W
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(5):799-803.
1996: Estey E; Pierce S
Routine bone marrow exam during first remission of acute myeloid leukemia.
Blood 1996;87(9):3899-902.
1996: Estey E; Thall P F; Mehta K; Rosenblum M; Brewer T; Simmons V; Cabanillas F; Kurzrock R; Lopez-Berestein G
Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid.
Blood 1996;87(9):3650-4.
1996: DeLima M; Ghaddar H; Pierce S; Estey E
Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above.
British journal of haematology 1996;93(1):89-95.
1996: Gandhi V; Estey E; Keating M J; Chucrallah A; Plunkett W
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Blood 1996;87(1):256-64.
1995: Kuschel B; Estey E
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
Leukemia & lymphoma 1995;20(1-2):153-5.
1995: Kornblau S M; Thall P; Huh Y O; Estey E; Andreeff M
Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(10):1735-41.
1995: Estey E; Andreeff M
Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(9):1440-3.
1995: Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan K W; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
Cytokines and molecular therapy 1995;1(2):115-22.
1995: Ghaddar H; Anderlini P; Estey E
Treatment of acute myelogenous leukemia.
The New England journal of medicine 1995;332(25):1717-8; author reply 1718-9.
1995: Estey E; Keating M J; Pierce S; Stass S
Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):972-6.
1995: Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich E J; Estey E
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):965-71.
1995: Spiekermann K; O'Brien S; Estey E
Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain.
Cancer 1995;75(7):1594-7.
1995: O'Brien S; Kantarjian H; Ellis A; Zwelling L; Estey E; Keating M
Topotecan in chronic lymphocytic leukemia.
Cancer 1995;75(5):1104-8.
1995: Gandhi V; Estey E; Du M; Nowak B; Keating M J; Plunkett W
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(2):169-78.
1995: Cortes J E; Kantarjian H; O'Brien S; Keating M; Pierce S; Freireich E J; Estey E
Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(1):115-7.
1995: Wetzler M; Kurzrock R; Estrov Z; Estey E; Talpaz M
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
Leukemia research 1995;19(1):23-34.
1994: Dimopoulos M A; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2694-8.
1994: Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich E J; Keating M; Pierce S; Estey E
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2174-8.
1994: Robertson L E; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating M J
Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2047-51.
1994: O'Brien S; Kurzrock R; Duvic M; Kantarjian H; Stass S; Robertson L E; Estey E; Pierce S; Keating M J
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
Blood 1994;84(3):733-8.
1994: Kornblau S M; Xu H J; Zhang W; Hu S X; Beran M; Smith T L; Hester J; Estey E; Benedict W F; Deisseroth A B
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia.
Blood 1994;84(1):256-61.
1994: Cortes J E; Kantarjian H; O'Brien S; Robertson L E; Koller C; Hirsh-Ginsberg C; Stass S; Keating M; Estey E
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
Cancer 1994;73(12):2946-52.
1994: Ferrajoli A; Talpaz M; Zipf T F; Hirsch-Ginsberg C; Estey E; Wolpe S D; Estrov Z
Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(5):798-805.
1994: Bodey G P; Anaissie E J; Elting L S; Estey E; O'Brien S; Kantarjian H
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
Cancer 1994;73(8):2099-106.
1994: Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson L E; Koller C; Kornblau S
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):671-8.
1994: O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
The New England journal of medicine 1994;330(5):319-22.
1994: Keating M J; O'Brien S; Plunkett W; Robertson L E; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Fludarabine phosphate: a new active agent in hematologic malignancies.
Seminars in hematology 1994;31(1):28-39.
1994: Preti A; Kantarjian H M; Estey E; Huh Y; Keating M; Pierce S; Hirsch-Ginsberg C; Yee G; Stass S A
Characteristics and outcome of patients with acute lymphocytic leukemia and myeloperoxidase-positive blasts by electron microscopy.
Hematologic pathology 1994;8(4):155-67.
1994: Gandhi V; Estey E; Plunkett W
Modulation of arabinosylcytosine metabolism during leukemia therapy.
Advances in experimental medicine and biology 1994;370():119-24.
1994: Keating M J; Estey E; O'Brien S; Kantarjian H; Robertson L E; Plunkett W
Clinical experience with fludarabine in leukaemia.
Drugs 1994;47 Suppl 6():39-49.
1993: Kantarjian H M; Estey E; O'Brien S; Anaissie E; Beran M; Pierce S; Robertson L; Keating M J
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Cancer 1993;72(10):2950-5.
1993: Suki S; Kantarjian H; Gandhi V; Estey E; O'Brien S; Beran M; Rios M B; Plunkett W; Keating M
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Cancer 1993;72(7):2155-60.
1993: Plunkett W; Gandhi V; Huang P; Robertson L E; Yang L Y; Gregoire V; Estey E; Keating M J
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Seminars in oncology 1993;20(5 Suppl 7):2-12.
1993: O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson L E; Lerner S; Keating M
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
Blood 1993;82(6):1695-700.
1993: Kurzrock R; Estey E; Talpaz M
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1489-95.
1993: Keating M J; O'Brien S; Kantarjian H; Plunkett W; Estey E; Koller C; Beran M; Freireich E J
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Blood 1993;81(11):2878-84.
1993: Kemena A; O'Brien S; Kantarjian H; Robertson L; Koller C; Beran M; Estey E; Plunkett W; Lerner S; Keating M J
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Robertson L E; Hall R; Keating M J; Estey E; Kantarjian H M; McLaughlin P; Hagemeister F B; Plunkett W
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Leukemia & lymphoma 1993;10(1-2):43-8.
1993: Kornblau S M; Cortes-Franco J; Estey E
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(3):378-83.
1993: Estey E; Plunkett W; Gandhi V; Rios M B; Kantarjian H; Keating M J
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Leukemia & lymphoma 1993;9(4-5):343-50.
1993: Dimopoulos M A; Kantarjian H; Estey E; O'Brien S; Delasalle K; Keating M J; Freireich E J; Alexanian R
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
Annals of internal medicine 1993;118(3):195-8.
1993: Derderian P M; Kantarjian H M; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
The American journal of medicine 1993;94(1):69-74.
1993: Gandhi V; Estey E; Keating M J; Plunkett W
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):116-24.
1993: Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman J U; Talpaz M
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Experimental hematology 1993;21(1):80-5.
1993: Gandhi V; Estey E; Keating M J; Plunkett W
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Leukemia & lymphoma 1993;10 Suppl():109-14.
1993: Keating M J; O'Brien S; Kantarjian H; Robertson L B; Koller C; Beran M; Estey E
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;10 Suppl():139-45.
1993: Estey E; Pierce S; Kantarjian H; O'Brien S; Beran M; Andreeff M; Escudier S; Koller C; Kornblau S; Robertson L
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Leukemia & lymphoma 1993;11 Suppl 2():59-63.
1992: Kornblau S M; Xu H J; del Giglio A; Hu S X; Zhang W; Calvert L; Beran M; Estey E; Andreeff M; Trujillo J
Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.
Cancer research 1992;52(17):4587-90.
1992: Zhang W; Hu G; Estey E; Hester J; Deisseroth A
Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells.
Oncogene 1992;7(8):1645-7.
1992: Claxton D F; Reading C L; Nagarajan L; Tsujimoto Y; Andersson B S; Estey E; Cork A; Huh Y O; Trujillo J; Deisseroth A B
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia.
Blood 1992;80(3):582-6.
1992: Estey E; Thall P F; Kantarjian H; O'Brien S; Koller C A; Beran M; Gutterman J; Deisseroth A; Keating M
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Blood 1992;79(9):2246-55.
1992: Estrov Z; Kurzrock R; Estey E; Wetzler M; Ferrajoli A; Harris D; Blake M; Gutterman J U; Talpaz M
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.
Blood 1992;79(8):1938-45.
1992: Chang K S; Lu J F; Wang G; Trujillo J M; Estey E; Cork A; Chu D T; Freireich E J; Stass S A
The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction.
Blood 1992;79(3):554-8.
1992: Estey E; Trujillo J M; Cork A; O'Brien S; Beran M; Kantarjian H; Keating M; Freireich E J; Stass S
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
Hematologic pathology 1992;6(1):43-8.
1992: Keating M J; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich E J
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():78-80.
1991: Kurzrock R; Talpaz M; Estey E; O'Brien S; Estrov Z; Gutterman J U
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(11):985-90.
1991: Kantarjian H M; Talpaz M; Dhingra K; Estey E; Keating M J; Ku S; Trujillo J; Huh Y; Stass S; Kurzrock R
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood 1991;78(9):2411-8.
1991: O'Brien S; Kantarjian H; Estey E; Koller C; Beran M; McCredie K; Keating M
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
Cancer 1991;68(4):691-4.
1991: O'Brien S; Benvenuto J A; Estey E; Beran M; Felder T B; Keating M
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Cancer research 1991;51(3):935-8.
1990: Hittelman W N; Tigaud J D; Estey E; Vadhan-Raj S
Premature chromosome condensation in the study of minimal residual disease.
Bone marrow transplantation 1990;6 Suppl 1():9-13.
1990: Gutterman J; Vadhan-Raj S; Logothetis C; Anaissle E; Estey E; Talpaz M; Kurzrock R
Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.
Seminars in hematology 1990;27(3 Suppl 3):15-24.
1990: Plunkett W; Heinemann V; Estey E; Keating M
Pharmacologically directed design of leukemia therapy.
Haematology and blood transfusion 1990;33():610-3.
1990: Keating M J; Kantarjian H; Estey E; Plunkett W; Trujillo J; McCredie K B
Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia.
Haematology and blood transfusion 1990;33():593-603.
1989: Keating M J; Kantarjian H; Smith T L; Estey E; Walters R; Andersson B; Beran M; McCredie K B; Freireich E J
Response to salvage therapy and survival after relapse in acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1071-80.
1989: Heinemann V; Estey E; Keating M J; Plunkett W
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(5):622-8.
1989: Estey E; Smith T L; Keating M J; McCredie K B; Gehan E A; Freireich E J
Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(4):257-63.
1987: Bakic M; Chan D; Andersson B S; Beran M; Silberman L; Estey E; Ricketts L; Zwelling L A
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Biochemical pharmacology 1987;36(23):4067-77.
1987: Estey E; Plunkett W; Dixon D; Keating M; McCredie K; Freireich E J
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1987;1(8):580-3.
1987: Estey E; Adlakha R C; Hittelman W N; Zwelling L A
Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity.
Biochemistry 1987;26(14):4338-44.
1987: Keating M J; Estey E; Kantarjian H M; Walters R; Smith T; McCredie K B; Freireich E J
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():120-6.
1987: Zwelling L A; Estey E; Bakic M; Silberman L; Chan D
Topoisomerase II as a target of antileukemic drugs.
NCI monographs : a publication of the National Cancer Institute 1987;(4):79-82.
1986: Bakic M; Beran M; Andersson B S; Silberman L; Estey E; Zwelling L A
The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
Biochemical and biophysical research communications 1986;134(2):638-45.

Sign-in to see more